SHMT2 regulates serine metabolism to promote the progression and immunosuppression of papillary renal cell carcinoma
Open Access
- 30 August 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 914332
Abstract
Recent research has demonstrated the diverse relationship between tumour metabolism and the tumour microenvironment (TME), for example, abnormal serine metabolism. This study investigated the role of serine metabolism in papillary renal cell carcinoma (pRCC) focusing on the prognostic value and regulatory mechanisms. Gene expression profiles and clinical data of patients with pRCC were obtained from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database. Kaplan–Meier curves were used for survival analysis and consensus clustering for tumour serine metabolic signatures extraction. Functional analysis, including the Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene set enrichment analysis (GSEA), was applied to explore the biological characteristics. The gene set variation analysis (GSVA), single-sample GSEA (ssGSEA), and Estimation of Stromal and Immune cells in Malignant Tumour tissues using Expression data (ESTIMATE) methods were utilised to estimate the immune infiltration in the various subtypes. Five serine metabolic genes (SMGs) were used to classify patients with pRCC, with four clusters identified with diverse prognoses and immune features based on these survival-related SMGs. Further analysis of the best and worst clusters (B and D clusters) revealed variations in survival, clinical progression, oncogenic pathways, and TME, which included immune infiltration scores, immunosuppressive cell infiltration, and expression of immune checkpoints. In addition, SMGs, especially SHMT2, exacerbated the carcinogenesis and immunosuppressive cells in pRCC, thus promoting tumour proliferation. In conclusion, higher SHMT2 gene expression and higher serine metabolism in tumour cells are associated with poorer clinical outcomes in pRCC. SHMT2 is a potential novel target gene for targeted therapy and immunotherapy in pRCC.Keywords
This publication has 44 references indexed in Scilit:
- Tissue-based map of the human proteomeScience, 2015
- Serine Catabolism Regulates Mitochondrial Redox Control during HypoxiaCancer Discovery, 2014
- pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression LevelsPLOS ONE, 2014
- Serine and glycine metabolism in cancerTrends in Biochemical Sciences, 2014
- Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell linesGenome Biology, 2014
- An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell CarcinomaCancer Cell, 2011
- Functional genomics reveal that the serine synthesis pathway is essential in breast cancerNature, 2011
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- How regulatory T cells workNature Reviews Immunology, 2008
- A Molecular Classification of Papillary Renal Cell CarcinomaCancer Research, 2005